High Risk Pregnancy
Conditions
Keywords
pregnancy, growth restriction
Brief summary
The purpose of this study is to test the application of newly generated magnetic resonance imaging (MRI) protocols for the assessment of placental perfusion in human subjects. The primary objective is to validate and establish the utility of placental MRI in pregnant women. The study will be entirely MRI-technology based with collection of placental tissue at the time of infant delivery for later correlative studies.
Detailed description
The placenta provides all the nutrition from a pregnant mother to a developing fetus. A placenta that functions normally is needed to ensure normal fetal growth and development. Unfortunately, the placenta is the least understood human organ even though it is involved in all pregnancy complications. The placenta is so poorly understood because our current methods to look at it during pregnancy, like ultrasound, do not provide enough information about placental growth and function. This study will help provide information about: * How the placenta grows and develops during pregnancy * How the placenta delivers nutrients, like oxygen to the developing fetus * If placental function using new advanced imaging tools can predict pregnancy complications like fetal growth restriction, stillbirth, preeclampsia and preterm labor This study will explore how blood flow to the placenta affects placental growth, fetal growth, and oxygen delivery to the fetus. Blood flow to the placenta may determine how the placenta supports fetal growth and development. Having a way to measure placental function during pregnancy may provide a way to understand normal pregnancies but importantly also identify pregnancies at increased risk for pregnancy complications. Additionally we want to have an ancillary intrauterine growth restriction (IUGR) arm; the objective of this ancillary study is to test the sensitivity of the placental MRI protocol in women with confirmed cases of IUGR in the third trimester.
Interventions
DEVICEMRI
Recently-developed placenta-specific magnetic resonance imaging (MRI) tools will be used to quantify maternal perfusion and oxygen transfer throughout pregnancy in 3 groups of human subjects: 1) non-smokers, 2) smokers, 3) individuals at high risk for adverse outcome. The objective of this work is to develop a new non-invasive clinical tool for early identification of placental dysfunction.
DEVICEMRI - IUGR
Recently-developed placenta-specific magnetic resonance imaging (MRI) tools will be used to quantify maternal perfusion and oxygen transfer throughout pregnancy. The objective of this ancillary arm is to further test the sensitivity of placental magnetic resonance imaging to detect abnormal perfusion and oxygenation in confirmed cases of IUGR between gestational ages 28 to 36 weeks.
Sponsors
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Oregon Health and Science University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 52 Years
Healthy volunteers
Yes
Inclusion criteria
Pregnant women will be recruited based on inclusion criteria for 3 subject groups: 1. Non-smokers with low risk for placental insufficiency 2. Smokers 3. Non-smokers who are at a high risk for adverse outcomes based on prior clinical history. Inclusion criteria: Pregnant women fulfilling inclusion criteria, and not meeting
Exclusion criteria
, will be invited to participate in this study. Inclusion criteria for all groups: 1. Maternal age over 18 years and able to give informed consent 2. Pregnant patient, as defined by positive pregnancy test for elevated β-human chorionic gonadotropin (HCG) and certain menstrual history, or early ultrasound, identified prior to 14 weeks of gestation Inclusion criteria for low risk group: 1. No history of a second or third trimester loss 2. No history of fetal growth restriction Inclusion criteria for high risk group: 1. History of pregnancy complicated by placental insufficiency in a previous singleton pregnancy (i.e. severe preeclampsia requiring preterm delivery, preterm delivery due to placenta insufficiency (eg. fetal growth restriction (FGR), oligohydramnios, abnormal umbilical artery Doppler's, abnormal antenatal testing), FGR \<10% delivered at term; stillbirth attributed to placental cause, regardless of gestational age 2. Not currently a smoker 3. Pregnancy at risk for placental insufficiency due to clinical concerns (eg. chronic hypertension) 4. Spontaneous preterm birth \<34 weeks
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Placental perfusion (Units of measure: ml/min) measured at 3 time points across gestation. | Change from 16, 24, and 32 weeks gestation | This will allow perfusion changes across pregnancy to be quantified in women from the three study groups. |
| Optimal cutoff values of placental MRI for placenta mediated adverse outcomes using receiver operating characteristics (ROC) | Change from 16, 24, and 32 weeks gestation | Determine the sensitivity and specificity of placental MRI at 16, 24, and 32 weeks gestation for identifying risk of adverse clinical outcome identified later in pregnancy. Optimal cutoff values of placental MRI for placenta mediated adverse outcomes using receiver operating characteristics (ROC). |
| Composite of placenta-mediated adverse pregnancy outcomes | 39 weeks gestation | A binary variable indication whether the placenta-mediated adverse pregnancy has observed within 39 weeks gestation Composite of placenta-mediated adverse pregnancy outcomes defined as the presence of at least one of the following: 1. Fetal death (not due to genetic or infectious etiology), 2. Preeclampsia or gestational hypertension, 3. Small for gestational age fetus \< 5%, 4. Oligohydramnios (defined as amniotic fluid index (AFI) \< 5 cm) prompting delivery prior to 39 weeks gestation, 5. Abnormal fetal heart rate tracing prompting delivery prior to 39 weeks gestation, 6. Abnormal umbilical artery Doppler velocimetry prompting delivery prior to 39 weeks gestation. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Composite of Placenta histologic outcomes | 39 weeks gestation | Composite of placental histologic outcomes defined as the presence of one of the following: 1. accelerated villous maturation 2. abnormal villous cytotrophoblast proliferation 3. microscopic infarctions 4. decidual vasculopathy |
| Gestational age at delivery prior to 37 weeks gestation. | 37 weeks gestation | — |
| Diagnosis of preeclampsia using standard clinical criteria | 39 weeks gestation | — |
| Small for gestational age fetus at 3% and 5% | 39 weeks gestation | — |
Countries
United States
Outcome results
None listed